For patients with advanced NSCLC, ICIs such as programmed cell death-1 (PD-1)/ programmed cell death ligand-1 (PD-L1) inhibitors have been approved for first-line treatment [14]. This evidence concerns the gene PDCD1 and non-small cell lung carcinoma.